American Hospital Association May 1, 2025
The AHA May 1 expressed concerns (LINK) to the Centers for Medicare & Medicaid Services about the payment process established under the Medicare Drug Price Negotiation Program, explaining ways it undermines the purpose of the 340B Drug Pricing Program. The Medicare Transaction Facilitator is intended to support data and payment exchanges among dispensing entities, plan sponsors and drug companies to implement drug discounts. However, CMS will only require dispensing entities, and not drug manufacturers, to participate in the payment module overseen by the MTF. This would allow drug manufacturers to establish their own payment systems outside of the MTF, making agency oversight more challenging. Additionally, CMS would let drug manufacturers make required discounted prices available retrospectively, which could jeopardize patient...
Today's Sponsors
Today's Sponsor